Company intelligence / Profile preview
Ablaris Therapeutics
Wayne, Pennsylvania, United Statesaclaristx.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Aclaris has multiple Phase 2 programs including zunsemetinib for rheumatoid arthritis, bosakitug for atopic dermatitis, lepzacitinib for moderate atopic dermatitis, and ATI-2138 for severe atopic dermatitis. The company recently licensed BSI-045B, which showed promising Phase 2a results in atopic dermatitis.
- Therapeutic areas
- OncologyDermatologyImmunology
- Modalities
- Small moleculesMonoclonal antibodiesBispecific antibodies
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Biosion, Inc.
Beyond the preview
Go deeper on Ablaris Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ablaris Therapeutics.